BioSpace News Archive

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase I/II clinical trial in advanced solid tumors.

XORTX Therapeutics Inc. announces that further to its news release dated August 13, 2021 the Company will complete a share consolidation of the issued and outstanding common shares of the Company on the basis of 11.74 pre-consolidation common shares for each one post-consolidation common share, as approved at the meeting of shareholders held on September 2, 2021.

Co-Diagnostics, Inc. (NASDAQ: CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson, Head of Investor Relations, will present and host one-on-one meetings with investors at the Sidoti Fall Virtual Investor Conference.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety of surufatinib (SULANDA® in China) in combination with toripalimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma (“NEC”) who have progression of disease or intolerable toxicity after previous first-line chemotherapy.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it has commenced an underwritten public offering of shares of its common stock and series B preferred stock (the “Series B Preferred”).

Novavax, Inc today announced that John J. Trizzino , Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at 8:50 a.m.

Immuneering Corporation today announced that Immuneering Corporation has been selected to be added to the Russell 2000® Index effective September 20, 2021, after the close of the U.S. equity markets.

aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the closing of an underwritten public offering of 10,781,250 shares of its common stock at a public offering price of $8.00 per share, which included the full exercise of the underwriters’ option to purchase additional shares.

Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its interim financial results for the six months ended June 30, 2021 and provided a corporate update.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021.